SEC Form 4 · accession 0001209191-18-049118
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ryan J. Watts
Officer — President and CEO · Director
Period of report
Aug 29, 2018
Accepted (ET)
Aug 31, 2018 · 5:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Aug 29, 2018 | S | 18,334 | $18.05 | D | 2,784,304 | I | See footnote |
| Common Stock | holding | — | — | — | 12,505 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- F2The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.